MedTrace Logo

Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

NCT06068686 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-02-04

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of vildagliptin on copeptin in comparison to glimepiride, and whether copeptin could be used as a marker for the efficacy of vildagliptin in type 2 diabetes mellitus patients, and how copeptin correlates with other diabetic and cardiac markers.

Conditions

Interventions

DRUG

Vildagliptin 50 MG

vildagliptin plus their metformin.

DRUG

Glimepiride 3 Mg Oral Tablet

glimepiride plus their metformin

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass Prof. · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-11-30
Completion
2024-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068686 on ClinicalTrials.gov